Get the Stockscreener App
182.48
0.39%
-0.7506
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $182.48, with a volume of 436.06K.
It is down -0.39% in the last 24 hours and down -2.30% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$183.23
Open:
$183.99
24h Volume:
436.06K
Relative Volume:
0.48
Market Cap:
$20.40B
Revenue:
$10.52B
Net Income/Loss:
$999.00M
P/E Ratio:
21.82
EPS:
8.3628
Net Cash Flow:
$1.22B
1W Performance:
-3.69%
1M Performance:
-2.30%
6M Performance:
+3.78%
1Y Performance:
+15.53%
1-Day Range:
$181.94
$184.73
1-Week Range:
$179.53
$197.55
52-Week Range:
$148.70
$197.55
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
182.44 | 20.38B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
574.28 | 215.96B | 43.74B | 6.59B | 6.17B | 17.30 |
|
DHR
Danaher Corp
|
223.21 | 157.33B | 24.27B | 3.50B | 4.86B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
643.07 | 51.09B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
147.96 | 41.80B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
221.14 | 37.38B | 15.70B | 1.24B | 2.01B | 6.9036 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
JPMorgan Adjusts Quest Diagnostics Price Target to $205 From $190 - MarketScreener
Is Quest Diagnostics Incorporated stock in correction or buying zoneGold Moves & Free Safe Entry Trade Signal Reports - newser.com
Exit strategy if you’re trapped in Quest Diagnostics Incorporated2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com
Can Quest Diagnostics Incorporated (QDI) stock retain market dominanceMarket Weekly Review & Precise Swing Trade Alerts - newser.com
How currency fluctuations impact Quest Diagnostics Incorporated stockRate Cut & High Conviction Buy Zone Picks - newser.com
Can Quest Diagnostics Incorporated stock surprise with earnings upsideJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
Argus Lifts Price Target on Quest Diagnostics to $210 From $195 - MarketScreener
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance
How to escape a deep drawdown in Quest Diagnostics IncorporatedWeekly Trend Summary & Target Return Focused Picks - newser.com
Truist Financial Reaffirms Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
How supply chain issues affect Quest Diagnostics Incorporated stockMarket Weekly Review & Growth Focused Investment Plans - newser.com
How dovish Fed policy supports Quest Diagnostics Incorporated stockPortfolio Risk Summary & Accurate Buy Signal Alerts - newser.com
What Fibonacci levels say about Quest Diagnostics Incorporated reboundWeekly Earnings Recap & Low Risk High Reward Ideas - newser.com
Will Quest Diagnostics Incorporated stock return to pre crisis levelsQuarterly Trade Report & Fast Moving Stock Watchlists - newser.com
Barclays Maintains Quest Diagnostics (DGX) Equal-Weight Recommendation - Nasdaq
Quest Diagnostics Incorporated (DGX): A Bull Case Theory - MSN
Quest Diagnostics: Strong Q3, Steady (Not Spectacular) Growth Ahead (NYSE:DGX) - Seeking Alpha
Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings - Benzinga
Quest Diagnostics Sees Solid Demand Even As Margins Slip - Finimize
Quest Diagnostics Margins a Blip as Fundamentals Stay Strong, Morgan Stanley Says - MarketScreener
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock - sharewise.com
Barclays Lifts Price Target on Quest Diagnostics to $195 From $190, Maintains Equalweight Rating - MarketScreener
Quest Diagnostics Reports Third Quarter 2025 Financial Results, Raises Guidance for Full Year 2025 - MarketScreener
Morgan Stanley Raises Price Target on Quest Diagnostics to $207 From $191, Keeps Overweight Rating - MarketScreener
Quest Diagnostics (DGX): 15.4% Earnings Growth Challenges Slower-Growth Narrative - Yahoo Finance
Quest Diagnostics: Q3 Earnings Snapshot - Stamford Advocate
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Will Quest Diagnostics Incorporated stock profit from fiscal stimulus2025 Dividend Review & Breakout Confirmation Trade Signals - newser.com
Jefferies Maintains Quest Diagnostics (DGX) Buy Recommendation - Nasdaq
Quest Diagnostics Inc (DGX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Published on: 2025-10-21 17:43:02 - newser.com
Leerink Partners Raises Price Target for Quest Diagnostics (DGX) to $210 | DGX Stock News - GuruFocus
Why Quest Diagnostics Incorporated stock is a strong buy call2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
Quest Diagnostics Inc (DGX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Quest Diagnostics Inc (DGX) Q3 2025 Earnings Call Highlights: St - GuruFocus
Leerink Partners Adjusts PT on Quest Diagnostics to $210 From $203, Maintains Outperform Rating - MarketScreener
Quest Diagnostics Reports Q3 Earnings, Shares Slide - Benzinga
Quest Diagnostics Incorporated Revises Financial Guidance for the Full Year Ending December 31, 2025 - MarketScreener
Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010. - MarketScreener
Fertility Test Market Report 2025-2033, with Profiles of Quest Diagnostics, Mayo Clinic Laboratories, Ovation Fertility, Illume Fertility, Proov, BioMerieux, Labcorp, CCRM Fertility, and Maven Clinic - Yahoo Finance
Quest Diagnostics shares rise as strong clinical demand drives earnings beat - Investing.com Australia
Quest Diagnostics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Quest Diagnostics (DGX) Surpasses Q3 Earnings and Revenue Estimates - sharewise.com
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - TradingView
Quest Diagnostics Ups Forecasts As Diagnostic Test Demand Rises - Finimize
Quest Diagnostics Q3 2025 Earnings: Revenue Surpasses Estimates at $2.82 Billion, Adjusted EPS at $2.60 - GuruFocus
Quest Diagnostics Q3 Adjusted Earnings, Revenue Rise; Annual Outlook Upgraded -- Shares Up Pre-Bell - MarketScreener
Quest Diagnostics Delivers Strong Growth And Raises Guidance - Finimize
Quest Diagnostics raises annual profit and revenue forecasts on lab test demand - MarketScreener
Quest Diagnostics (DGX) Exceeds Q3 Projections with Strong Finan - GuruFocus
Quest (NYSE:DGX) Posts Better-Than-Expected Sales In Q3 - The Globe and Mail
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):